{
  "docId": "019dd923-622c-750b-8b9a-21918ac10c17",
  "docSlug": "f3db2294dcf9",
  "documentTitle": "Harmony Biosciences (HRMY)",
  "authorId": "58_Scorpion_Capital",
  "authorName": "Scorpion Capital",
  "documentKindSlug": "research-note",
  "documentKindLabel": "Research note",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2023-03-28 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 115,
  "pageCount": 366,
  "prevPage": 114,
  "nextPage": 116,
  "slideType": "expose_contradiction",
  "function": "expose_contradiction",
  "density": "dense",
  "nDataPoints": 6,
  "notes": "The slide uses a red underline to emphasize the specific clinical findings in the excerpt.",
  "elementsJson": [
    "paragraph",
    "screenshot",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9a-21918ac10c17/115",
  "deckHref": "/decks/019dd923-622c-750b-8b9a-21918ac10c17",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-21918ac10c17.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-21918ac10c17#slide-115",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "The abstract states “no cardiovascular or other significant safety concern,” yet three patients on pitolisant had at least one prolonged QT interval >450 msec and 4 patients had at least one QTc longer than 60 msec - and one patient in the pitolisant group died due to cardiopulmonary failure (heart attack)",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd953-64d0-7099-9cd2-17290f6717d5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.48,
        "x": 0.07,
        "y": 0.59
      },
      "kind": "paragraph",
      "text": "groups. However, in the pitolisant treatment group, three patients (1.5%) had at least one postdose corrected QT interval by Fredericia’s corrected QT interval (QTcF) longer than 450 ms, and four patients (2.0%) had one QTcF elongation greater than or equal to 60 ms, whereas there was one patient with QTcF longer than 450 ms in the placebo group.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0e7d03e2-4e8a-4c41-b503-829bd344e9da",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.45,
        "x": 0.07,
        "y": 0.52
      },
      "kind": "paragraph",
      "text": "Pitolisant for Daytime Sleepiness in Patients with Obstructive Sleep Apnea Who Refuse Continuous Positive Airway Pressure Treatment A Randomized Trial",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "10231e5f-f1fb-4a59-9f0e-b588fc437867",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.38,
        "w": 0.86,
        "x": 0.07,
        "y": 0.07
      },
      "kind": "paragraph",
      "text": "HAROSA 2 exhibited an even more troubling cardiotoxicity signal, including a fatality – also conducted at half the maximal dose and again excluding patients with significant cardiovascular histories. The abstract states “no cardiovascular or other significant safety concern,” yet three patients on pitolisant had at least one prolonged QT interval >450 msec and 4 patients had at least one QTc longer than 60 msec - and one patient in the pitolisant group died due to cardiopulmonary failure (heart attack) - with only one patient in the placebo group experiencing QTcF >450 in placebo, no placebo patients experiencing QTcF >60 msec and no deaths in the placebo group. And again the same red flag - the investigators compare placebo to treatment at the end of study and do not disclose baseline to treatment changes in these patients.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f1493dd6-d764-40c2-954c-b48e6e20f78f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "“no cardiovascular or other significant safety concern,” — HAROSA 2 Abstract",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd953-64d0-7099-9cd2-1a4906b34bbb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.35,
        "x": 0.07,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7193861/",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "30c21a20-f589-4fc3-94a5-ff64fc5d1f23",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.33,
        "x": 0.07,
        "y": 0.48
      },
      "kind": "title",
      "text": "HAROSA 2 publication - excerpt",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "759e1d03-9e27-4729-8792-f6867851fed4",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "fraud-exposure",
      "slug": null,
      "matchId": "b53b68c0-ecaf-4acf-8f99-2c72061c7eee",
      "evidence": "Contrasting abstract claims with raw data to expose misleading reporting.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}